RHYTHM™
BIOSCIENCES



Rhythm Biosciences

An ASX Life Sciences Growth Opportunity

POST-AGM PRESENTATION

ASX: RHY

Disclaimer



This presentation has been prepared by **Rhythm Biosciences Limited** (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

Detecting cancer earlier to save lives

Rhythm Biosciences is an ASX-listed company building a precision diagnostics platform focused on earlier cancer detection, risk assessment and improved patient outcomes.

COLOSTAT®

Who has the disease?

Non-invasive, blood-based bowel cancer detection that improves colonoscopy triage.

geneType™

Who is at risk?

Genomic cancer risk assessment that identifies elevated risk before symptoms emerge.

Rhythm is positioned at the intersection of precision medicine, preventative healthcare and scalable diagnostics.



Cancer is often detected too late

Earlier detection significantly improves survival outcomes and lowers treatment costs.

RHYTHM BIOSCIENCES

15,500+

new colorectal cancer cases diagnosed every year in Australia

>50%

diagnosed as late-stage disease (Stages III or IV)

10%

5-year survival rate when diagnosed at Stage IV



FY26 Commitments review

Commitments made at the last AGM and the milestones reported through FY26

Commitment (AGM 2025)	Target	Status	Evidence
ColoSTAT®: final clinical validation	Q3 CY 2025	Q3 CY 2025	ASX announcement 26 August 2025
geneType™: strategic partnerships	Q3 CY 2025	Q3 CY 2025	ASX announcement 28 August 2025
geneType™: menu expansion	Q4 CY 2025	Q1 CY 2026	ASX announcement 14 January 2026
ColoSTAT®: in-house IVD launch (subject to NATA review)	Q4 CY 2025	Q4 CY 2025	ASX announcement 12 December 2025
ColoSTAT®: commercialisation and development partnerships	Q1 CY 2026	Q1 CY 2026	ASX announcement 17 February 2026
Lung cancer screening assay: pre-clinical data evaluation	Q2 CY 2026	Q3 CY 2026	Genetype lung test: ASX announcement 21 July 2026

OTHER FY26 PROGRESS COMMUNICATED TO THE MARKET (JULY 2025 TO JUNE 2026)

- **Dec 2025:** NHS England evaluation of ColoSTAT® agreed; began Feb 2026
- **Jan 2026:** First peer-reviewed ColoSTAT® clinical performance paper
- **Feb 2026:** Commercial manufacturing agreement with Quansys Biosciences
- **Feb 2026:** First physician in ColoSTAT® Access Program
- **Feb 2026:** $5.2m secured for the RHYO option exercise
- **Mar 2026:** ColoSTAT® added to NATA-accredited scope (ISO 15189:2022)
- **Mar 2026:** First ColoSTAT® sale; 78 collection sites active by 31 March
- **Mar 2026:** SE Asian geneType™ distribution deal and first regional sale


RHYTHM™
BIOSCIENCES
COLOSTAT®
Colorectal Cancer Test
A blood-based colorectal cancer detection platform designed to aid effective early diagnosis.
www.colostat.com

ColoSTAT®: from build to launch

The milestones that turned a test into a commercial product

RHYTHM BIOSCIENCES

DEVELOPMENT: 2003 TO 2026

2003 – 2004

Biomarker discovery

Candidate protein markers identified



2005 – 2014

Clinical evaluation

Biomarkers evaluated in patient samples

CSIRO

2019 – 2022

Pivotal study

Prospective study in ~900 patients

SONIC CLINICAL TRIALS

2024 – 2025

Assay development

Design and testing of the multiplex assay

QUANSYS BIOSCIENCES

March 2026

NATA accreditation

ColoSTAT® added to NATA-accredited scope

NATA
WORLD RECOGNISED ACCREDITATION

LAUNCH MILESTONES IN FY26 (JULY 2025 TO JUNE 2026)

Dec. 2025

NHS England

Evaluation of ColoSTAT® agreed

Feb. 2026

Manufacturing Agreement

Supply agreement completed

Feb. 2026

Partnership

4Cyte Pathology: national collection network established

March 2026

First sale

First commercial ColoSTAT® sale

SINCE 30 JUNE 2026

- ✓ TGA in-house IVD notification completed
- ✓ Ordering live in Medical Director (1 August 2026)
- ✓ Ordering live in Best Practice (Bp Premier), November 2026
- ✓ Expanded to 130+ patient-facing blood collection sites

22 million patients waiting on a colonoscopy decision...

Representing a global market opportunity of >$5bn

22M symptomatic patients could benefit from better-informed colonoscopy decisions. That's approximately **40% of annual colonoscopy** volumes worldwide.

An alternative to stool-based testing
Many patients avoid stool-based testing, delaying diagnosis

Prioritise patients at greatest risk
Help specialists identify which symptomatic patients should receive colonoscopy sooner.

Reduce unnecessary invasive procedures
Support alternative clinical management for patients less likely to benefit from colonoscopy.

Alleviate accessibility challenges
Regional and underserved communities face limited access to endoscopy facilities.

Estimated annual triage opportunity by region

Millions of potential tests per year



Global annual opportunity: 22M tests p.a.

ColoSTAT® is a simple blood test that tells the specialist who to scope first.

Building the foundations to open the market

ColoSTAT® focus for FY27 and beyond: five pieces close the circle



1. **Scientific evidence UNLOCKS Scientific credibility**
   Peer-reviewed publications and conference data on ColoSTAT®

2. **Intellectual property UNLOCKS A defensible position**
   One family of patents under prosecution in multiple jurisdictions

3. **Clinical evidence UNLOCKS Clinician confidence**
   Independent review of the data, including NATA approval

4. **Economic evidence UNLOCKS Funding access**
   Build on the independent economic study (~$4.50 of hospital costs avoided per $1) and initial engagement with Medicare (MSAC) process

5. **Commercial evidence UNLOCKS Partners and revenue growth**
   GP ordering, repeat orders and collection sites; expand partnerships

= complete all five and ColoSTAT® becomes a proven, protected, funded and growing market

Source: Rhythm Biosciences Q1 FY27 Quarterly Activities Report and Appendix 4C (27 October 2026).

Generating additional clinical evidence

Four types of evidence, being built by health systems and physicians

RHYTHM BIOSCIENCES

EVIDENCE WE NEED TO CREATE

1. Real world evidence
2. Expanding use cases
3. System-specific experiences
4. Increasing statistical confidence

CLINICAL SITES AND STUDY STATUS

1. **ColoSTAT® Access Program**
   A network of physicians using ColoSTAT® in routine practice
2. **NHS**
   Technology transfer completed; patient testing underway
3. **A Victorian Health Network**
   Developing clinical evaluation protocol
4. **A Queensland Health Network**
   Submission of joint grant application
5. **A New South Wales Health Network**
   Developing clinical evaluation protocol

Generating Commercial Evidence: How we grow revenue

Four ColoSTAT® growth levers that multiply each other – all already in motion

RHYTHM BIOSCIENCES

LEVER 1

More doctors ordering

Making ColoSTAT® well known to GPs and specialists and easy to order.

ALREADY IN MOTION

- Digital campaign for patients and GPs
- Electronic ordering now in place

×

LEVER 2

More collection sites

More places close to home for patients to give a blood sample.

ALREADY IN MOTION

- 100+ 4Cyte sites across the eastern states (up from 78)
- Continued expansion planned

×

LEVER 3

Reimbursement

A Medicare listing would make ColoSTAT® more affordable for eligible patients. Hospital budgets will be accessible with relevant data.

ALREADY IN MOTION

- Independent study: ~$4.50 of hospital costs avoided per $1 spent on testing
- Initial MSAC engagement in Q2 FY27
- Hospital studies in development

×

LEVER 4

International markets

Running ColoSTAT® in partner labs overseas opens up new countries.

ALREADY IN MOTION

- NHS England lab can now run the test (technology transfer complete)
- Patient-sample testing in the NHS evaluation is underway

More doctors ordering × more collection sites × Medicare funding × new international markets

= more ColoSTAT® tests, more patients helped and more revenue

Source: Rhythm Biosciences Q1 FY27 Quarterly Activities Report and Appendix 4C (27 October 2026).

Blood collection, close to home

The 4Cyte network now spans the east coast, with more sites opening

RHYTHM BIOSCIENCES

4CYTE COLLECTION NETWORK | NOVEMBER 2026

78 → 130+

4Cyte Pathology

collection sites: from 78 at the end of March 2026 to over 100 today

Comprehensive electronic ordering

Clinical by Telstra Health

BpPremier

- ✓ **Standardised electronic ordering leads to more straightforward ordering**
- ✓ **Proximity to patient's homes increases ease of access**



Source: Rhythm Biosciences Q1 FY27 Quarterly Activities Report and Appendix 4C (27 October 2026); 4Cyte collection network, November 2026.

ColoSTAT® orders are building from a range of customers

A rare first-in-class, Australia-first product launch

RHYTHM BIOSCIENCES

COLOSTAT® TEST ORDERS PER MONTH, 2026



Linear trend (ordinary least squares, n = 10 months): y = 2.715x – 1.933, R^2 = 0.91, where x = month number (January = 1).



Source: Rhythm Biosciences business analytics report FY27 (monthly ColoSTAT® orders, actuals); repeat-order share per Rhythm management; order locations from ColoSTAT® order data (16 November 2026), one dot per town.

ColoSTAT® puts the patient first

Three patients, one blood test: reassurance, a way in, or urgency within days

RHYTHM BIOSCIENCES



Female, 59
Office worker

Anxious, facing a 60-day wait

WHY THEY CAME IN

Abdominal pain, anaemia on recent bloods and an uncle with bowel cancer.

WHAT COLOSTAT® CHANGED

A negative result eased her distress while she waited for her colonoscopy.

Colonoscopy at day 57 confirmed no cancer



Male, 77
Retired bank clerk

Declined a colonoscopy

WHY THEY CAME IN

Persistent abdominal pain and swelling; he cited the colonoscopy prep and sedation as being an obstacle.

WHAT COLOSTAT® CHANGED

He asked for another option. A positive result prompted a recall, and he agreed to a colonoscopy.

Colonoscopy found early-stage cancer



Male, 58
Uber driver

Thought it was haemorrhoids

WHY THEY CAME IN

Blood in his stool and a positive FOBT, but he feared the colonoscopy and long local wait.

WHAT COLOSTAT® CHANGED

A positive result moved him to category 1 and an urgent colonoscopy.

Colonoscopy found bowel cancer

Within days, ColoSTAT® gave each patient what they needed: reassurance, a way in, or urgency.

RHYTHM™ BIOSCIENCES

geneType™

Personalised cancer risk assessment designed to support earlier detection and prevention.

www.genetype.com



Personalised cancer risk assessment at scale

geneType™ CANCER RISK ASSESSMENT PLATFORM

RHYTHM™ BIOSCIENCES

How geneType™ reaches the market



Projected test volume mix across the forecast period, with most volume expected to come through enterprise accounts and strategic partners.

Clinics – 25%

Direct volume: healthcare professionals (B2B). Clinics provide an immediate route to patients and support early test uptake.

Enterprise – 75%

Pathology networks, health, insurance and other enterprise partners can extend access across larger populations.

A broader cancer portfolio

Six cancer risk assessments, including three that complement Rhythm's protein biomarker programs.

- Breast*
- Prostate
- Colorectal*
- Ovarian
- Pancreatic*
- Melanoma

* Rhythm Biosciences protein biomarker program overlap.
Lung cancer test pending transfer to production.

A single platform covering six cancers, delivered through clinics and enterprise partners.

geneType™: Enterprise partner pipeline across four regions

The Company has a rich pipeline of new business partnership opportunities

RHYTHM BIOSCIENCES

Current Strategic Partners

CancerIQ · agrf · silesHealth · Rockville Gynecology · my performance doctor · Gene by Gene · Catch · Know Your Lemons · 4Cyte Pathology · Evergreen Doctors · BHIPM

North America



POTENTIAL LEADS (RELATIVE)



HEALTHCARE MARKET
US$5.6T US + Canada

POPULATION AGED 30–69
≈200M US + Canada

Europe



POTENTIAL LEADS (RELATIVE)



HEALTHCARE MARKET
US$1.9T EU-27

POPULATION AGED 30–69
≈240M EU-27

Asia



POTENTIAL LEADS (RELATIVE)



HEALTHCARE MARKET
US$1.3T+ China only

POPULATION AGED 30–69
≈2.4B Asia region

Australia



POTENTIAL LEADS (RELATIVE)



HEALTHCARE MARKET
US$0.18T A$270B

POPULATION AGED 30–69
≈14M

SEEKING PARTNERS IN FOUR SECTORS

- Pathology providers
- Diagnostic companies
- Healthcare providers
- Insurers

Healthcare market: CMS National Health Expenditure 2024 (US); CIHI 2025 (Canada); Eurostat 2023 (EU-27, excludes UK); China National Health Commission 2024 (Asia shown for China only); AIHW 2023–24 (Australia, A$270.5B). Population aged 30–69 is an estimate based on UN World Population Prospects 2024 totals and typical age structure. Funnel size indicates relative number of potential leads.

geneType™ finds the risk routine screening misses

Three patients, one risk assessment: a different pathway for each

RHYTHM BIOSCIENCES



Female, 43
Teacher

Dense breasts, no family history

WHY THEY CAME IN

Mammogram at 41; considering another now or waiting a few more years.

WHAT GENETYPE™ CHANGED

An increased-risk result led her doctor to add a breast MRI.

MRI found LCIS; now on risk-reducing medication



Male, 51
Electrician

Waiting for his next bowel kit

WHY THEY CAME IN

No family history. His bowel screening kit at 50 was negative, and the next was planned at 52.

WHAT GENETYPE™ CHANGED

An increased-risk result led his doctor to order a colonoscopy instead.

Five polyps removed, including two advanced adenomas



Male, 60
Small business owner

Borderline PSA for four years

WHY THEY CAME IN

PSA mildly raised four years in a row, but never high enough to warrant follow-up.

WHAT GENETYPE™ CHANGED

An increased-risk result prompted a prostate MRI, then a biopsy.

Biopsy found localised, aggressive Gleason 8 cancer

geneType™ moved each patient from routine screening to the right next test.

Commercial portfolio supported by a strong pipeline

Seven tests on the market today; a pipeline across nine cancers

RHYTHM BIOSCIENCES



	BREAST	PROSTATE	COLORECTAL	OVARIAN	MELANOMA	PANCREATIC	LUNG	GASTRIC	CERVICAL
Risk Assessment	●	●	●	●	●	●	◕	○	·
Screening	○	·	◕	·	·	○	◕	○	○
Triage	·	·	●	·	·	·	◕	○	·
Biopsy	·	·	·	·	·	·	·	·	·
Surgical Margins	·	·	·	·	·	·	·	·	·
Drug Management	·	·	·	·	·	·	·	·	·
Monitoring	·	·	·	·	·	·	·	·	·

● Commercial product
◕ Active development program
○ Near-future opportunity
· Future opportunity

FY27 Key value inflection points

Milestone (FY27)	Quarter	Status
ColoSTAT® ordering in Best Practice	Q2 FY27	Completed
Continued expansion of 4Cyte collection centers	Q2 FY27	In progress
Digital campaign for patients and GPs	Q2 FY27	In progress
NHS patient-sample research testing begins	Q2 FY27	In progress
FY26 R&D Tax Incentive claim lodged	Q2 FY27	In progress
Establish ColoSTAT® evaluation project with major Australian hospital	Q3 FY27	In progress
geneType™ strategic partnerships: partner funnel expanding	Q3 FY27	In progress
ColoSTAT® MSAC pre-submission	Q3 FY27	In progress
Interim real-world evidence analysis from the ColoSTAT® Access Program	Q4 FY27	In progress
Initial design confirmed for 3rd generation blood-based CRC detection test (designed for asymptomatic testing)	Q4 FY27	In progress

Why Rhythm Biosciences? Why now?



Dual-platform precision diagnostic products & pipeline

Longitudinal disease management: combining personalised risk assessment and earlier cancer detection.

Large global addressable markets

Exposure to significant and growing global cancer diagnostics demand.

Commercialisation underway

Development risks reduced. Commercial validation, partnerships and rollout progressing across several markets.

Team

Experienced diagnostics leadership executing the next phase of commercial growth



David Atkins, PhD
CEO & MD

Former CEO of Congenica (UK) & Synevo Diagnostics, Sr. Executive at Johnson & Johnson and Danaher.

Founder of Veridex – cancer molecular and cellular diagnostics (USA).

Experience in product development and commercial leadership in the global medical device and diagnostic industry. Also, an active member of BioNSW and InGeNA.



Sue MacLeman
Interim Non-Executive Chair

30 years in Pharma, Biotech and Medtech including Amgen, BMS and Merck and SMEs.

Experienced Board member, former CEO of NASDAQ, ASX, & AIM entities. Currently Chair of Medicines Australia, NED & Chair at Viral Vector Manufacturing Facility, Smartways Logistics, Healthcare Translation Group, OMICO & member of the National Research Infrastructure (NRI) Advisory Group.



Carl Stubbings
Non-Executive Director

Experienced diagnostics executive, including 13 years in the USA as SVP of Panbio USA and VP Sales & Marketing at Focus Diagnostics (Quest Diagnostics).

Former CEO & MD of Sienna Cancer Diagnostics, COO of BARD1 and CCO of Genetic Technologies.

Currently Chair of Diag-Nose Medical and NED of Sangui Bio.



Maureen Baker
Non-Executive Director

25+ years in investment banking and securities, including Head of Regional Equity Sales at Deutsche Bank (Hong Kong) and MD, Australian Sales at CLSA.

NED of Acorn Capital Investment Fund (ASX: ACQ), where she chairs the Risk and Audit Committee, and of Vmoto (ASX: VMT).

BCom (Melbourne), MBA (Melbourne Business School), GAICD.



Adam Zembrzuski
Chief Commercial Officer



Gary Goh
Director of Operations & Quality



Dr. Erika Spaeth
Director of geneType™ Clinical & Scientific Affairs



Dr. Andy Feber
Director of Diagnostic Clinical & Scientific Affairs

RHYTHM™
BIOSCIENCES

Thank you & Questions

David Atkins, PhD
david.atkins@rhythmbio.com
www.rhythmbio.com